BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 34568801)

  • 1. Autophagy-mediated reduction of miR-345 contributes to hepatic cystogenesis in polycystic liver disease.
    Masyuk T; Masyuk A; Trussoni C; Howard B; Ding J; Huang B; LaRusso N
    JHEP Rep; 2021 Oct; 3(5):100345. PubMed ID: 34568801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cholangiocyte autophagy contributes to hepatic cystogenesis in polycystic liver disease and represents a potential therapeutic target.
    Masyuk AI; Masyuk TV; Lorenzo Pisarello MJ; Ding JF; Loarca L; Huang BQ; LaRusso NF
    Hepatology; 2018 Mar; 67(3):1088-1108. PubMed ID: 29023824
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical manifestation, epidemiology, genetic basis, potential molecular targets, and current treatment of polycystic liver disease.
    Mahboobipour AA; Ala M; Safdari Lord J; Yaghoobi A
    Orphanet J Rare Dis; 2024 Apr; 19(1):175. PubMed ID: 38671465
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autophagy promotes hepatic cystogenesis in polycystic liver disease by depletion of cholangiocyte ciliogenic proteins.
    Masyuk AI; Masyuk TV; Trussoni CE; Pirius NE; LaRusso NF
    Hepatology; 2022 May; 75(5):1110-1122. PubMed ID: 34942041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of Cdc25A suppresses hepato-renal cystogenesis in rodent models of polycystic kidney and liver disease.
    Masyuk TV; Radtke BN; Stroope AJ; Banales JM; Masyuk AI; Gradilone SA; Gajdos GB; Chandok N; Bakeberg JL; Ward CJ; Ritman EL; Kiyokawa H; LaRusso NF
    Gastroenterology; 2012 Mar; 142(3):622-633.e4. PubMed ID: 22155366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic Targets in Polycystic Liver Disease.
    Masyuk TV; Masyuk AI; LaRusso NF
    Curr Drug Targets; 2017; 18(8):950-957. PubMed ID: 25915482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MicroRNA15a modulates expression of the cell-cycle regulator Cdc25A and affects hepatic cystogenesis in a rat model of polycystic kidney disease.
    Lee SO; Masyuk T; Splinter P; Banales JM; Masyuk A; Stroope A; Larusso N
    J Clin Invest; 2008 Nov; 118(11):3714-24. PubMed ID: 18949056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cAMP effectors Epac and protein kinase a (PKA) are involved in the hepatic cystogenesis of an animal model of autosomal recessive polycystic kidney disease (ARPKD).
    Banales JM; Masyuk TV; Gradilone SA; Masyuk AI; Medina JF; LaRusso NF
    Hepatology; 2009 Jan; 49(1):160-74. PubMed ID: 19065671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3',5'-cyclic monophosphate.
    Masyuk TV; Masyuk AI; Torres VE; Harris PC; Larusso NF
    Gastroenterology; 2007 Mar; 132(3):1104-16. PubMed ID: 17383431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetics and mechanisms of hepatic cystogenesis.
    van de Laarschot LFM; Drenth JPH
    Biochim Biophys Acta Mol Basis Dis; 2018 Apr; 1864(4 Pt B):1491-1497. PubMed ID: 28782656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutations in GANAB, Encoding the Glucosidase IIα Subunit, Cause Autosomal-Dominant Polycystic Kidney and Liver Disease.
    Porath B; Gainullin VG; Cornec-Le Gall E; Dillinger EK; Heyer CM; Hopp K; Edwards ME; Madsen CD; Mauritz SR; Banks CJ; Baheti S; Reddy B; Herrero JI; Bañales JM; Hogan MC; Tasic V; Watnick TJ; Chapman AB; Vigneau C; Lavainne F; Audrézet MP; Ferec C; Le Meur Y; Torres VE; ; ; Harris PC
    Am J Hum Genet; 2016 Jun; 98(6):1193-1207. PubMed ID: 27259053
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic Spectrum of Polycystic Kidney and Liver Diseases and the Resulting Phenotypes.
    Yang H; Sieben CJ; Schauer RS; Harris PC
    Adv Kidney Dis Health; 2023 Sep; 30(5):397-406. PubMed ID: 38097330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multi-omics profiling of cholangiocytes reveals sex-specific chromatin state dynamics during hepatic cystogenesis in polycystic liver disease.
    Ji R; Chen J; Xie Y; Dou X; Qing B; Liu Z; Lu Y; Dang L; Zhu X; Sun Y; Zheng X; Zhang L; Guo D; Chen Y
    J Hepatol; 2023 Apr; 78(4):754-769. PubMed ID: 36681161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting UBC9-mediated protein hyper-SUMOylation in cystic cholangiocytes halts polycystic liver disease in experimental models.
    Lee-Law PY; Olaizola P; Caballero-Camino FJ; Izquierdo-Sanchez L; Rodrigues PM; Santos-Laso A; Azkargorta M; Elortza F; Martinez-Chantar ML; Perugorria MJ; Aspichueta P; Marzioni M; LaRusso NF; Bujanda L; Drenth JPH; Banales JM
    J Hepatol; 2021 Feb; 74(2):394-406. PubMed ID: 32950589
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TGR5 contributes to hepatic cystogenesis in rodents with polycystic liver diseases through cyclic adenosine monophosphate/Gαs signaling.
    Masyuk TV; Masyuk AI; Lorenzo Pisarello M; Howard BN; Huang BQ; Lee PY; Fung X; Sergienko E; Ardecky RJ; Chung TDY; Pinkerton AB; LaRusso NF
    Hepatology; 2017 Oct; 66(4):1197-1218. PubMed ID: 28543567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New insights into targeting hepatic cystogenesis in autosomal dominant polycystic liver and kidney disease.
    Barten TRM; Bernts LHP; Drenth JPH; Gevers TJG
    Expert Opin Ther Targets; 2020 Jun; 24(6):589-599. PubMed ID: 32250187
    [No Abstract]   [Full Text] [Related]  

  • 17. Liver cyst gene knockout in cholangiocytes inhibits cilium formation and Wnt signaling.
    Wills ES; Te Morsche RHM; van Reeuwijk J; Horn N; Geomini I; van de Laarschot LFM; Mans DA; Ueffing M; Boldt K; Drenth JPH; Roepman R
    Hum Mol Genet; 2017 Nov; 26(21):4190-4202. PubMed ID: 28973524
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modelling polycystic liver disease progression using age-adjusted liver volumes and targeted mutational analysis.
    Sierks D; Schönauer R; Friedrich A; Hantmann E; de Fallois J; Linder N; Fischer J; Herber A; Bergmann C; Berg T; Halbritter J
    JHEP Rep; 2022 Nov; 4(11):100579. PubMed ID: 36246085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ursodeoxycholic acid inhibits hepatic cystogenesis in experimental models of polycystic liver disease.
    Munoz-Garrido P; Marin JJ; Perugorria MJ; Urribarri AD; Erice O; Sáez E; Úriz M; Sarvide S; Portu A; Concepcion AR; Romero MR; Monte MJ; Santos-Laso Á; Hijona E; Jimenez-Agüero R; Marzioni M; Beuers U; Masyuk TV; LaRusso NF; Prieto J; Bujanda L; Drenth JP; Banales JM
    J Hepatol; 2015 Oct; 63(4):952-61. PubMed ID: 26044126
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.